Psychomotor therapy's effect on quality of life in depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of personalized psychomotor therapy in improving the quality of life for individuals diagnosed with major depressive disorder (MDD). Participants will be randomly assigned to receive either standard treatment alone or standard treatment plus weekly psychomotor therapy sessions for three months. The study aims to assess changes in quality of life and psychomotor profiles at three and six months. A total of 128 participants will be involved, with assessments focusing on various psychomotor skills and overall well-being.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of depressive episode according to DSM-5 criteria.
* HDRS \> 16
* Hospitalized or followed-up in one of the participating centers.
* Affiliated or beneficiary of a social security scheme.
* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).

Exclusion Criteria:

* Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders)
* Sensory impairment or proven neurological pathology
* History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes)
* Limited functional ability (difficulty in moving about, performing manual tasks or moving about)
* Inability to understand questionnaires and study information
* Inability to travel to the inclusion center (personal vehicle, public transport)
* Pregnant or breast-feeding women, on declaration
* Forced hospitalization, subjects under guardianship or trusteeship, lack of social protection

Where it's running

• CH Esquirol
  Limoges, France Recruiting

Study contacts

• Study coordinator: Aude PAQUET, Dr
• Email: aude.paquet@ch-esquirol-limoges.fr
• Phone: +33555431127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• Accelerated vs Standard iTBS for Major Depression

  This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07768397

• Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD

  This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.

  Recruiting Phase 3 Khyber Medical University Peshawar · Islamabad, Capital and 2 other locations · NCT07703722

• Magnesium Bisglycinate Added to Your Depression Treatment

  This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.

  Recruiting All India Institute of Medical Sciences, Bhubaneswar · Bhubaneswar, Odisha · NCT07633080

• Motif XCS System for treatment-resistant depression

  This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.

  Recruiting at 4 sites Motif Neurotech, Inc. · Atlanta, Georgia and 3 other locations · NCT07594483

• A Phase 3 test of DT120 for major depressive disorder

  DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.

  Recruiting at 23 sites Phase 3 Definium Therapeutics US, Inc. · Little Rock, Arkansas and 25 other locations · NCT07592689

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.